(Q34373482)

1 August 2017

title

Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients (English)

1 reference

1 August 2017

0 references

0 references

P Karlsson

1

1 reference

1 August 2017

L Smith

2

1 reference

1 August 2017

L Farde

3

1 reference

1 August 2017

C Härnryd

4

1 reference

1 August 2017

G Sedvall

5

1 reference

1 August 2017

F A Wiesel

6

1 reference

1 August 2017

publication date

1 October 1995

1 reference

1 August 2017

1 reference

1 August 2017

volume

121

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

309-316

1 reference

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF02246068

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02246068

Psychopharmacologic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02246068

Imaging of neurotransmitter receptors in the living human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02246068

Pharmacological agents affecting emesis. A review (Part I)

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

D-1 dopamine receptor stimulation elevates plasma prolactin levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Mechanism of the antipsychotic effect in the treatment of acute schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

A rating scale for drug-induced akathisia

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Evidence that neuroleptics increase striatal acetylcholine release through stimulation of dopamine D1 receptors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

The central effects of a novel dopamine agonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine-C14 in brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Two directions of dopamine D1/D2 receptor interaction in studies of behavioural regulation: a finding generic to four new, selective dopamine D1 receptor antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Molecular biology of dopamine receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

The reversal of extrapyramidal side effects with SCH 39166, a dopamine D1 receptor antagonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

[3H]SCH 39166, a new D1-selective radioligand: in vitro and in vivo binding analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Clinical Evaluation of Sulpiride in Schizophrenic Patients - A Double-blind Comparison with Chlorpromazine

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Interrater reliability of the Structured Clinical Interview for the Positive and Negative Syndrome Scale for schizophrenia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Oral administration of NNC 756 — a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

An open clinical and biochemical study of ritanserin in acute patients with schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

A clinical comparison of melperone and placebo in schizophrenic women on a milieu therapeutic ward.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Observations of Placebo Response in Chronic Schizophrenic Patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8584611

12 December 2020

Identifiers

DOI

10.1007/BF02246068

1 reference

Dimensions Publication ID

1 August 2017

1012968849

0 references

1 reference